Source: CureToday articles
In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better.
Recent Content
- Triplet regimen extends OS in relapsed or refractory multiple myeloma
- Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
- Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
- QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making
- Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma
- Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
- Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
- Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma
- FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma
- KRd56 Versus KRd27 Shows Similar Effectiveness, Safety in R/R Multiple Myeloma